Steroid sidestep: evading androgen ablation by abiraterone.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25432158.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2899 and PMC identifier 4359949.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer.
Medical subject headings
- Androstenes
- Progesterone
- Prostatic Neoplasms, Castration-Resistant
- Receptors, Androgen
- Steroid 17-alpha-Hydroxylase